BackgroundCheck.run
Search For

Dong D Hwang, 56Memphis, TN

Known as:
Dong Jin Hwang Dong J Hwang Jin Hwang Dongjin Dongjin Hwang Dong-Jin Hwang
Related to:
Luke J Hwang 26

Dong Hwang Phones & Addresses

Bartlett, TN   

Saint Paul, MN   

5162 Jon Oak Dr, Arlington, TN 38002    901-2905302   

Shiloh, TN   

Social networks

Dong D Hwang

Linkedin

Work

Company: Institute for healthcare improvement Sep 2008 Position: Internal auditor

Education

Degree: BS School / High School: University of Alabama at Birmingham 1995 to 2001 Specialities: Accounting

Industries

Accounting
Get Report
Control this profile

Mentions for Dong D Hwang

Career records & work history

Medicine Doctors

Dong H. Hwang

Specialties:
Obstetrics & Gynecology
Work:
Northeast Medical Services
1520 Stockton St, San Francisco, CA 94133
415-3919686 (phone) 408-9220872 (fax)
Site
Dong Ha Hwang MD
402 8 Ave STE 201, San Francisco, CA 94118
415-8316068 (phone)
Education:
Medical School
Seoul Natl Univ, Coll of Med, Chongno Ku, Seoul, So Korea
Graduated: 1971
Procedures:
Cesarean Section (C-Section), Circumcision, Cystoscopy, Delivery After Previous Caesarean Section, Hysterectomy, Myomectomy, Oophorectomy, Tubal Surgery, Vaccine Administration, Vaginal Delivery, Vaginal Repair
Conditions:
Abnormal Vaginal Bleeding, Breast Disorders, Conditions of Pregnancy and Delivery, Genital HPV, Spontaneous Abortion, Uterine Leiomyoma, Acne, Anemia, Candidiasis of Vulva and Vagina, Complicating Pregnancy or Childbirth, Constipation, Dermatitis, Endometriosis, Female Infertility, Fractures, Dislocations, Derangement, and Sprains, Gastrointestinal Hemorrhage, Hemorrhoids, Herpes Genitalis, Hypertension (HTN), Iron Deficiency Anemia, Menopausal and Postmenopausal Disorders, Non-Toxic Goiter, Plantar Warts, Skin and Subcutaneous Infections, Tinea Pedis, Uncomplicated or Low Risk Pregnancy and Delivery, Urinary Incontinence, Urinary Tract Infection (UT)
Languages:
English, Korean
Description:
Dr. Hwang graduated from the Seoul Natl Univ, Coll of Med, Chongno Ku, Seoul, So Korea in 1971. He works in San Francisco, CA and 1 other location and specializes in Obstetrics & Gynecology. Dr. Hwang is affiliated with California Pacific Medical Center California Campus and Chinese Hospital.

Dong S. Hwang

Specialties:
Colon & Rectal Surgery
Work:
Dong S Hwang MD
900 Wind Riv Ln STE 106, Gaithersburg, MD 20878
301-9771851 (phone) 301-9771853 (fax)
Education:
Medical School
UMDNJ New Jersey Medical School at Newark
Graduated: 1989
Conditions:
Abdominal Hernia, Anal Fissure, Anal or Rectal Abscess, Benign Polyps of the Colon, Cholelethiasis or Cholecystitis, Gastrointestinal Hemorrhage, Hemorrhoids, Malignant Neoplasm of Colon, Overweight and Obesity, Rectal, Abdomen, Small Intestines, or Colon Cancer
Languages:
English, Korean
Description:
Dr. Hwang graduated from the UMDNJ New Jersey Medical School at Newark in 1989. He works in Gaithersburg, MD and specializes in Colon & Rectal Surgery.
Dong Hwang Photo 1

Dong Soo Hwang

Specialties:
Surgery
Colon & Rectal Surgery
Education:
UMDNJ (1989)

License Records

Dong Hwan Hwang

Licenses:
License #: CC-0008406 - Active
Category: Accountancy
Issued Date: Apr 2, 2009
Type: C.P.A. Certificate

Dong S Hwang

Licenses:
License #: MT022451T - Expired
Category: Medicine
Type: Graduate Medical Trainee

Dong Hwan Hwang

Licenses:
License #: CC-0008406 - Active
Category: Accountancy
Issued Date: Apr 2, 2009
Type: C.P.A. Certificate

Dong Hwang resumes & CV records

Resumes

Dong Hwang Photo 29

Internal Auditor At Ihi

Position:
Internal Auditor at Institute for Healthcare Improvement
Location:
Cambridge, Massachusetts
Industry:
Accounting
Work:
Institute for Healthcare Improvement since Sep 2008
Internal Auditor Accounting Management Solutions Jun 2006 - Sep 2008
Senior Consultant Jumpstart - Greater Boston Area Mar 2002 - Jun 2006
Controller
Education:
University of Alabama at Birmingham 1995 - 2001
BS, Accounting

Publications & IP owners

Us Patents

Multi-Substituted Selective Androgen Receptor Modulators And Methods Of Use Thereof

US Patent:
7705182, Apr 27, 2010
Filed:
Feb 24, 2003
Appl. No.:
10/371155
Inventors:
James T. Dalton - Upper Arlington OH, US
Duane D. Miller - Germantown TN, US
Mitchell S. Steiner - Germantown TN, US
Karen A. Veverka - Cordova TN, US
Dong Jin Hwang - Memphis TN, US
Jiyun Chen - Columbus OH, US
Assignee:
University of Tennessee Research Foundation - Knoxville TN
International Classification:
C07C 233/05
A61K 31/16
US Classification:
564175, 564155, 558417, 514616, 514617, 514522, 514524
Abstract:
This invention provides androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. Other SARM compounds have been found to have an unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor. The SARM compounds, either alone or as a composition, are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of acute and/or chronic muscular wasting conditions; e) preventing and/or treating dry eye conditions; f) oral androgen replacement therapy; and/or g) decreasing the incidence of, halting or causing a regression of prostate cancer.

Multi-Substitued Selective Androgen Receptor Modulators And Methods Of Use Thereof

US Patent:
7803970, Sep 28, 2010
Filed:
Jun 7, 2004
Appl. No.:
10/861905
Inventors:
James T. Dalton - Upper Arlington OH, US
Duane D. Miller - Germantown TN, US
Mitchell S. Steiner - Germantown TN, US
Karen A. Veverka - Cordova TN, US
Dong Jin Hwang - Memphis TN, US
Jiyun Chen - Columbus OH, US
Assignee:
University of Tennessee Research Foundation - Knoxville TN
International Classification:
C07C 233/05
A61K 31/65
US Classification:
564175, 564153, 564155, 564158, 558413, 514493, 514520, 514522, 514616
Abstract:
This invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. Other SARM compounds have been found to have an unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor. The SARM compounds, either alone or as a composition, are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of acute and/or chronic muscular wasting conditions; e) preventing and/or treating dry eye conditions; f) oral androgen replacement therapy; and/or g) decreasing the incidence of, halting or causing a regression of prostate cancer.

Irreversible Selective Androgen Receptor Modulators And Methods Of Use Thereof

US Patent:
2004008, May 6, 2004
Filed:
Feb 24, 2003
Appl. No.:
10/371209
Inventors:
James Dalton - Upper Arlington OH, US
Duane Miller - Germantown TN, US
Mitchell Steiner - Germantown TN, US
Karen Veverka - Cordova TN, US
Leonid Kirkovsky - San Diego CA, US
Arnab Mukherjee - Saline MI, US
Dong Hwang - Memphis TN, US
International Classification:
C07F007/22
C07C331/00
C07C381/00
US Classification:
556/107000, 558/014000, 558/017000, 558/418000, 560/358000
Abstract:
In one embodiment, this invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). The SARM compounds have unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor. In one embodiment, the SARM compounds bind irreversibly to the androgen receptor. In another embodiment, the SARM compounds are androgen receptor antagonists which bind irreversibly to the androgen receptor. In another embodiment, the SARM compounds are alkylating agents. The SARM compounds, either alone or as a composition, are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of acute and/or chronic muscular wasting conditions; e) preventing and/or treating dry eye conditions; f) oral androgen replacement therapy; g) decreasing the incidence of, halting or causing a regression of prostate cancer; and/or h) inducing apoptosis in a cancer cell.

Irreversible Selective Androgen Receptor Modulators And Methods Of Use Thereof

US Patent:
2006003, Feb 16, 2006
Filed:
Nov 24, 2004
Appl. No.:
10/995567
Inventors:
James Dalton - Upper Arlington OH, US
Duane Miller - Germantown TN, US
Mitchell Steiner - Germantown TN, US
Karen Veverka - Cordova TN, US
Leonid Kirkovsky - San Diago CA, US
Dong Hwang - Bartlett TN, US
Arnab Mukherjee - Saline MI, US
International Classification:
C07C 331/28
US Classification:
514514000, 564161000, 558017000
Abstract:
In one embodiment, this invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). The SARM compounds have unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor. In one embodiment, the SARM compounds bind irreversibly to the androgen receptor In another embodiment, the SARM compounds are androgen receptor antagonists, which bind irreversibly to the androgen receptor. In another embodiment, the SARM compounds are alkylating agents. The SARM compounds, either alone or as a composition, are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of acute and/or chronic muscular wasting conditions; e) preventing and/or treating dry eye conditions; f) oral androgen replacement therapy; g) decreasing the incidence of, halting or causing a regression of prostate cancer; and/or h) inducing apoptosis in a cancer cell.

Indoles, Derivatives, And Analogs Thereof And Uses Therefor

US Patent:
2009014, Jun 4, 2009
Filed:
Nov 29, 2007
Appl. No.:
11/947668
Inventors:
James Dalton - Upper Arlington OH, US
Duane Miller - Germantown TN, US
Sunjoo Ahn - Columbus OH, US
Charles Duke, III - Memphis TN, US
Dong Jin Hwang - Germantown TN, US
Jun Yang - Amherst NY, US
International Classification:
C07D 403/08
C12N 5/00
C07D 209/04
US Classification:
435375, 548454, 548491
Abstract:
Indole derivatives and analog compounds and pharmaceutical compositions comprising the same are provided. Also provided are methods of using these compounds to inhibit tubulin polymerization in a cell associated with a proliferative disease or to treat a cancer.

Multi-Substituted Selective Androgen Receptor Modulators And Methods Of Use Thereof

US Patent:
2011008, Apr 7, 2011
Filed:
Sep 13, 2010
Appl. No.:
12/880389
Inventors:
James T. Dalton - Lakeland TN, US
Duane D. Miller - Germantown TN, US
Mitchell S. Steiner - Germantown TN, US
Karen A. Veverka - Cordova TN, US
Dong Jin Hwang - Bartlett TN, US
Jiyun Chen - Newbury Park CA, US
International Classification:
A61K 31/167
C07C 233/15
A61P 15/16
A61P 35/00
A61P 27/04
US Classification:
514622, 564175
Abstract:
This invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. Other SARM compounds have been found to have an unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor. The SARM compounds, either alone or as a composition, are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of acute and/or chronic muscular wasting conditions; e) preventing and/or treating dry eye conditions; f) oral androgen replacement therapy; and/or g) decreasing the incidence of, halting or causing a regression of prostate cancer.

Indoles, Derivatives And Analogs Thereof And Uses Therefor

US Patent:
2012002, Jan 26, 2012
Filed:
Jul 25, 2011
Appl. No.:
13/190150
Inventors:
James T. DALTON - Lakeland TN, US
Duane D. MILLER - Germantown TN, US
Sunjoo AHN - Memphis TN, US
Charles DUKE - Memphis TN, US
Dong Jin HWANG - Arlington TN, US
Jun YANG - Rockville MD, US
International Classification:
A61K 31/404
C07D 209/12
C07D 277/64
C07D 263/57
A61P 35/04
A61K 31/4184
A61K 31/423
A61K 31/428
A61P 35/00
C07D 403/10
C07D 235/22
US Classification:
514367, 548455, 514414, 548491, 514419, 548180, 548217, 5483094, 514395, 514375
Abstract:
Indole derivatives and analogous compounds and pharmaceutical compositions comprising the same are provided. Also provided are methods of using these compounds to inhibit tubulin polymerization in a cell associated with a proliferative disease or to treat cancer, metastatic cancer, resistant cancer or multidrug resistant cancer, including inter-alia: prostate cancer, breast cancer, melanoma, colon cancer and bladder cancer.

Possible Relatives

David Hwang  Dean Hwang  Debbie Hwang  Dan Hwang  Daniel Hwang  Aaron Hwang  Dennis J Hwang  Dong J Jun  Dong Jung  Dong Kang 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.